Empower Pharmacy urges action on FDA peptide compounding review
The FDA is accepting public comments on seven substances until July 9.
See the latest news and media coverage for Empower Pharmacy. We track all announcements, press releases, and industry mentions in real time, all in one place.
Accredited compounding pharmacy and FDA-registered outsourcing facility
empowerpharmacy.comLast updated
In short: Empower Pharmacy defended against a lawsuit from Eli Lilly, took legal action against former executives, and engaged in regulatory discussions.
The FDA is accepting public comments on seven substances until July 9.
The session covered sustainable remediation, aseptic practices, and evolving regulatory expectations.
The FDA's advisory committee will consider moving peptides to 503A bulks list, potentially restoring compounding access.
The national recognition reflects growth and commitment to quality in compounded medications.
Traditionally, compounding pharmacies exist to serve a small subset of patients who have specialized medical needs. But millions have taken compounded GLP-1s.
Multiple experts who reviewed the donation say the payment could qualify as a conflict because it has the potential to influence prescribing decisions.
Empower Pharmacy, a large GLP-1 compounding pharmacy that’s faced allegations of poor quality drugs and a legal challenge from Eli Lilly, has stopped operations at...
There has previously been some excellent reporting about patient safety concerns at Empower Pharmacy, a well-known compounding company that makes compounded GLP-1s.
Track Empower Pharmacy and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.